MK-677, also called ibutamoren, is an oral ghrelin mimetic that increases growth hormone and IGF-1. It is often sold beside injectable peptides, but it is not a peptide. Randomized human trials provide more data than exist for many research secretagogues: they show higher GH/IGF-1 and increased fat-free mass, but no demonstrated strength or functional benefit, no meaningful reduction in visceral fat, and concerning changes in glucose handling, appetite and fluid balance. MK-677 is not FDA approved, and its benefit-risk profile does not support casual "muscle-building" or anti-aging claims.
What is MK-677 and how does it work?
Ibutamoren is a non-peptide small molecule that activates GHSR-1a, the ghrelin or growth hormone secretagogue receptor. Because it can be taken orally and produces sustained receptor activity, its exposure pattern differs from short synthetic peptides such as GHRP-2 and ipamorelin.
GHSR activation stimulates pulsatile growth hormone secretion and can raise IGF-1. It also affects appetite and may influence glucose regulation, fluid retention, cortisol and prolactin. The mechanism therefore predicts both desired biomarker changes and potential harms.
Calling MK-677 a "growth hormone booster" is incomplete. The useful question is whether those hormonal effects improve a clinical outcome without creating unacceptable risk.
What randomized trials found
Older adults: more fat-free mass, not more function
A two-year randomized, double-blind, modified-crossover trial enrolled 65 healthy adults aged 60 to 81. At one year, average fat-free mass fell by 0.5 kg in the placebo group and rose by 1.1 kg in the MK-677 group. Body weight increased more with MK-677: 2.7 kg versus 0.8 kg.
The result often quoted online stops there. The trial also found:
- no significant reduction in abdominal visceral fat or total fat mass;
- no improvement in strength or physical function;
- an average fasting-glucose increase of about 5 mg/dL;
- decreased insulin sensitivity;
- increased appetite, mild lower-extremity edema and muscle pain among common effects.
Fat-free mass includes intracellular and extracellular water as well as muscle tissue. The investigators reported body-water changes consistent with an anabolic effect, which is another reason not to relabel the entire difference as new functional muscle.
Adults with obesity: no fat-loss result
In an eight-week randomized trial involving 24 men with obesity, MK-677 raised GH, IGF-1 and IGF-binding protein-3 and increased fat-free mass. Total and visceral fat did not significantly change. An oral glucose-tolerance test showed impaired glucose homeostasis at both two and eight weeks.
This study directly challenges the common claim that higher GH from MK-677 reliably produces fat loss. The trial measured body composition and did not find that outcome.
| Claim | Relevant human result | Evidence-based conclusion |
|---|---|---|
| "Builds muscle" | Fat-free mass increased in older adults | Composition changed, but strength and function did not |
| "Burns visceral fat" | No significant visceral-fat reduction in two randomized populations | Not established |
| "Improves recovery" | No robust injury or rehabilitation outcome trial | Unproven |
| "Safe oral alternative to GH" | Glucose, edema, appetite and potential heart-failure concerns | Misleading comparison |
| "A peptide" | Chemically a non-peptide ghrelin mimetic | Incorrect |
Why body-composition language matters
Lean mass, fat-free mass and skeletal muscle are not synonyms. Dual-energy X-ray absorptiometry estimates non-fat tissue but cannot determine whether every change is contractile protein. A compound that promotes fluid retention can increase scale weight and fat-free mass without improving what a reader actually cares about: strength, mobility or injury resilience.
A convincing sarcopenia treatment would need to improve function, not merely a scan. The older-adult trial's failure to improve strength or function is therefore not a side note; it is central to interpreting the apparent anabolic signal.
FDA safety findings and regulatory status
MK-677 is not FDA approved. In September 2025, FDA warned consumers about a children's product found to contain undeclared ibutamoren. The agency listed increased appetite, water retention, fatigue, muscle pain, altered glucose metabolism and insulin sensitivity, and possible increased congestive-heart-failure risk in some individuals.
FDA also places ibutamoren mesylate in category 2 for both 503A and 503B compounding. A randomized hip-fracture recovery trial was stopped early after a potential congestive-heart-failure signal. FDA's detailed review identifies hyperglycemia, liver-enzyme elevations, edema and fluid overload among serious concerns.
These signals do not mean every exposed person will develop heart failure. They do mean that the compound cannot responsibly be presented as a low-risk supplement, particularly for older adults or people with diabetes, cardiovascular disease, edema or multiple medicines.
Unknowns remain around long-term malignancy risk from sustained IGF-1 elevation, use during pregnancy, pediatric exposure and interactions. An online seller cannot close these gaps with a batch assay.
MK-677 compared with peptide secretagogues
MK-677's oral activity is a convenience, not evidence of safety.
| Compound | Chemistry and pathway | Most informative clinical point |
|---|---|---|
| MK-677 | Non-peptide oral GHSR agonist | Longer trials show fat-free-mass change plus glucose and fluid concerns |
| Ipamorelin | Pentapeptide GHSR agonist | Human phase 2 trial did not meet efficacy endpoints |
| GHRP-2 | Hexapeptide GHSR agonist | Short human studies show appetite and multi-hormone effects |
| CJC-1295 | GHRH analogue | Long-acting DAC form raises GH/IGF-1 for days; therapeutic benefit unproven |
There is no robust evidence that combining MK-677 with another secretagogue creates better functional outcomes. It may instead intensify downstream effects and complicate attribution.
What readers in Thailand and athletes should check
Search any purported finished medicine in the Thai FDA drug database, using the brand, manufacturer and registration number. A product described as a supplement or research chemical may still contain a pharmacologically active unapproved drug. FDA's 2025 hidden-ingredient finding shows why the label alone is not reliable evidence.
MK-677 is also prohibited in tested sport. The 2026 WADA Prohibited List explicitly names ibutamoren among growth hormone secretagogues prohibited at all times.
Common MK-677 interpretation mistakes
- Calling fat-free mass "muscle gain" without mentioning water or function.
- Omitting the negative visceral-fat result from body-composition claims.
- Ignoring glucose-tolerance findings because fasting glucose looks modest.
- Treating oral administration as inherently safer than injection.
- Describing an unapproved drug as a supplement.
- Quoting the older-adult trial without the heart-failure signal found in a different vulnerable population.
Frequently asked questions
Is MK-677 a peptide?
No. MK-677, or ibutamoren, is an orally active non-peptide small molecule. It is grouped with peptides because it activates the ghrelin receptor and stimulates growth hormone release.
Does MK-677 build functional muscle?
A randomized trial found increased fat-free mass in older adults, but no improvement in strength or physical function. Fat-free mass also includes water, so it should not be equated with functional muscle gain.
Is MK-677 FDA approved?
No. FDA states that ibutamoren is not approved and warns about appetite, fluid retention, muscle pain, altered glucose metabolism and a possible congestive-heart-failure risk in some people.
The decision-relevant takeaway
MK-677 demonstrates why biomarkers and body-composition scans must be connected to outcomes. It raises GH and IGF-1 and can increase fat-free mass, but trials did not show better strength, function or visceral-fat loss and did identify metabolic and fluid-related concerns. A person worried about muscle loss or hormone deficiency should seek a diagnosis and evidence-based plan, using the peptide evidence hub and ipamorelin comparison to avoid category and outcome confusion.